Our HPAPI capacities include 2 production facilities and 6 production lines, both dedicated and shared/multipurpose. These facilities are designed to handle the production of highly potent active pharmaceutical ingredients (HPAPIs) with the utmost precision and safety, ensuring the highest quality of products.
Our current annual production is 200 kg, utilizing 50% of our manufacturing capacity. This allows us significant flexibility to scale up operations as needed. The commercial batch sizes range from 200g to 8kg, accommodating both small-scale and large-scale production needs. We also have the capability to add additional equipment to our existing facilities for the production of new HPAPIs, ensuring we can meet the evolving needs of our customers.
As leaders in the R&D field for creating Anthracycline molecules, we have a proven track record of producing scientifically validated, high-quality products. Our advanced technology and state-of-the-art facilities enable us to maintain stringent quality control measures, ensuring that all our products are scientifically proven to be the best quality on the market. Furthermore, we can customize our production lines to any Anthracycline product, providing tailored solutions to meet specific customer requirements.
Our production capacities are currently underutilized, and we have the potential to double our production output. This can be further increased by incorporating night shifts, allowing us to maximize our manufacturing capabilities. Our esteemed R&D team, known for their innovative and ingenious approaches, is actively working on developing new molecules and expanding our knowledge base.
We are open to collaborations with Big Pharma for developing new molecules, leveraging our advanced R&D capabilities and extensive production experience. By partnering with us, companies can benefit from our state-of-the-art facilities, dedicated team, and commitment to excellence in producing high-quality HPAPIs. Together, we can push the boundaries of pharmaceutical innovation and bring new, effective treatments to the market.
In summary, Synbias-Gemini Group offers advanced technologies and capabilities that ensure the production of the highest quality HPAPIs. Our facilities are flexible and scalable, allowing us to meet diverse production needs and collaborate effectively with industry leaders to develop and produce new, innovative pharmaceutical solutions.
Our website uses only essential cookies that are necessary for its proper functioning. We do not use cookies for tracking or advertising purposes. For more details, please refer to our Privacy policy.